Annotation Detail
Information
- Associated Genes
- EGFR
- Associated Variants
-
EGFR MUTATION
EGFR MUTATION - Associated Disease
- peritoneal mesothelioma
- Source Database
- CIViC Evidence
- Description
- 25 patients with metastatic peritoneal mesothelioma were treated with surgical cytoreduction consolidated with intraperitoneal hyperthermic chemotherapy (CRS/IPHC). 8 of the patients carried EGFR mutations in the tyrosine kinase domain. Each mutation was not found in 100 unrelated controls. At study end 10/18 wildtype patients had died with median survival of 14 months, while 2/7 EGFR mutant patients had died and median survival was not yet reached. Median time to progression (TTP) was 12 months in the wildtype group and in the mutant group median TTP was not yet reached. 3 year progression free survival was 71% in the mutant group and 28% in the wildtype group.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/5923
- Gene URL
- https://civic.genome.wustl.edu/links/genes/19
- Variant URL
- https://civic.genome.wustl.edu/links/variants/442
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Peritoneal Mesothelioma
- Evidence Direction
- Supports
- Drug
- Cytoreductive Surgery,Hyperthermic Intraperitoneal Chemotherapy
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 20942962
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Cytoreductive Surgery | Sensitivity | true |
| Hyperthermic Intraperitoneal Chemotherapy | Sensitivity | true |